Skip to main content
SpringerLink
Log in

Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The therapy of ITP has recently been revolutionized with the introduction of thrombopoeitin stimulating agents. However, these medications are known to increase the platelet count only while the medication is being administered, with a rapid fall of the platelet count to baseline pre-therapy levels on discontinuation. We report the case of a patient with chronic refractory ITP who has attained a prolonged remission after a short course of eltrombopag, with normalization of the platelet count, which is sustained 8 months after discontinuation of the medication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989;320:974–80.

    Article  PubMed  CAS  Google Scholar 

  2. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, Nugent DJ. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102:887–95.

    Article  PubMed  CAS  Google Scholar 

  3. McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol. 2005;81:94–9.

    Article  PubMed  CAS  Google Scholar 

  4. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80:33–40.

    Article  PubMed  CAS  Google Scholar 

  5. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;34:995–1008.

    Article  Google Scholar 

  6. Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenicpurpura: a retrospective analysis. J Pediatr Hematol Oncol. 2003;25:660–4.

    Article  PubMed  Google Scholar 

  7. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005;106:2244–51.

    Article  PubMed  CAS  Google Scholar 

  8. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–47.

    Article  PubMed  CAS  Google Scholar 

  9. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641–8.

    Article  PubMed  CAS  Google Scholar 

  10. Bussel JB, Cheng G, Saleh MN, Meddeb B, Bailey C, Stone N, Aivado M. Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura. Blood. 2008;112:3432.

    Google Scholar 

  11. Bussel JB, Psaila B, Saleh MN, Vasey S, Mayer B, Stone N, Arning M. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura. Blood. 2008;112:3431. (abstract 3431).

    Google Scholar 

  12. McHutchinson JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J. TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227–36.

    Article  Google Scholar 

  13. Baranwal A, Fraser L, Jayawardene D, Jagiello-Gruszfeld A, Bondarenko I, Mendoza J. Efficacy and safety of eltrombopag, a novel, oral platelet growth factor on platelet counts in patients with cancer receiving carboplatin/paclitaxel chemotherapy. Support Care Cancer. 2007;15:761. (abstract P-168).

    Google Scholar 

  14. Khalafallah A, Rahman Z, Ogden K, Hannan T. Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia. Mediterr J Hematol Infect Dis. 2012;4:e2012003.

    Article  PubMed  Google Scholar 

  15. Vlachaki E, Papageorgiou V, Klonizakis F, Spandonidou M, Chisan S, Vetsiou E, et al. Total remission of severe immune thrombocytopenia after short term treatment with romiplostim. Hematol Rep. 2011;3:e20.

    Article  PubMed  Google Scholar 

  16. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377:393–402.

    Article  PubMed  CAS  Google Scholar 

  17. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457–69.

    Article  PubMed  CAS  Google Scholar 

  18. Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene. 2002;21:3359–67.

    Article  PubMed  CAS  Google Scholar 

  19. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonist-induced aggregation in platelets in vitro. FEBS Lett. 1995;374:48–52.

    Article  PubMed  CAS  Google Scholar 

  20. Rojnuckarin P, Drachman JG, Kaushansky K. Thrompoietin-induced activation of the mitogenactivated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood. 1999;94:1273–82.

    PubMed  CAS  Google Scholar 

  21. Drachman JG, Millet KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not Tyk2. J Biol Chem. 1999;274:13480–4.

    Article  PubMed  CAS  Google Scholar 

  22. Hayes S, Ouellet D, Zhang J, Wire MB, Gibiansky E. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol. 2011;51:1403–17.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Tata Memorial Hospital, Dr E Borges Rd, Parel, Mumbai, 400012, India

    V. Noronha, S. D. Philip, A. Joshi & K. Prabhash

Authors
  1. V. Noronha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. D. Philip
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Prabhash
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Prabhash.

About this article

Cite this article

Noronha, V., Philip, S.D., Joshi, A. et al. Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura. Int J Hematol 96, 380–382 (2012). https://doi.org/10.1007/s12185-012-1154-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-012-1154-2

Keywords

Search

Navigation